Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease
Oliveira-Silva, Jaquelline Carla Valamiel de; Machado-de-Assis, Girley Francisco; Oliveira, Maykon Tavares; Paiva, Nívia Carolina Noguieira; Araújo, Márcio Sobreira Silva; Carneiro, Cláudia Martins; Martins-Filho, Olindo Assis; Martins, Helen Rodrigues; Lana, Marta de.
Mem. Inst. Oswaldo Cruz;
110(1): 86-94, 03/02/2015. tab, graf
Artículo
en Inglés
| LILACS | ID: lil-741617
Trypanosoma cruzi strains from distinct geographic areas show differences in drug resistance and association between parasites genetic and treatment response has been observed. Considering that benznidazole (BZ) can reduce the parasite burden and tissues damage, even in not cured animals and individuals, the goal is to assess the drug response to BZ of T. cruzi II strains isolated from children of the Jequitinhonha Valley, state of Minas Gerais, Brazil, before treatment. Mice infected and treated with BZ in both phases of infection were compared with the untreated and evaluated by fresh blood examination, haemoculture, polymerase chain reaction, conventional (ELISA) and non-conventional (FC-ALTA) serologies. In mice treated in the acute phase, a significant decrease in parasitaemia was observed for all strains. Positive parasitological and/or serological tests in animals treated during the acute and chronic (95.1-100%) phases showed that most of the strains were BZ resistant. However, beneficial effect was demonstrated because significant reduction (p < 0.05%) and/or suppression of parasitaemia was observed in mice infected with all strains (acute phase), associated to reduction/elimination of inflammation and fibrosis for two/eight strains. BZ offered some benefit, even in not cured animals, what suggest that BZ use may be recommended at least for recent chronic infection of the studied region.
Biblioteca responsable:
BR1.1
Texto completo